Deaths Prompt Stronger Warning on Antibiotic
From Times Wire Reports
Sanofi-Aventis has put a stronger warning on its antibiotic Ketek after the deaths of four patients who took the drug and developed liver failure, U.S. regulators said.
Liver failure was reported in eight other Ketek users, including one who required a liver transplant as a result, the Food and Drug Administration said. Twenty-three others developed less serious liver damage, the FDA said.
Ketek was approved in 2004 to treat certain types of sinusitis, bronchitis and pneumonia, including cases that resist other antibiotics.
